LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression. The company's product portfolio also includes various strategic portfolio initiatives, such as transcatheter mitral valve replacement, an implant device for the treatment of mitral regurgitation through the replacement of native mitral valve; VITARIA to treat heart failure through VNS; and ANTHEM-HFpEF to study autonomic regulation therapy in patients experiencing symptomatic heart failure with preserved ejection fraction, as well as treatment resistant depression. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LIVN
CUSIPN/A
Phone44-0-20-3325-0660
Debt
Debt-to-Equity Ratio0.03
Current Ratio1.85
Quick Ratio1.51
Price-To-Earnings
Trailing P/E Ratio31.41
Forward P/E Ratio32.49
P/E Growth3.1
Sales & Book Value
Annual Sales$1.01 billion
Price / Sales4.97
Cash Flow$5.65 per share
Price / Cash18.40
Book Value$37.65 per share
Price / Book2.76
Profitability
EPS (Most Recent Fiscal Year)$3.31
Net Income$-25,080,000.00
Net Margins-1.99%
Return on Equity9.23%
Return on Assets6.60%
Miscellaneous
Employees4,500
Outstanding Shares48,440,000
LivaNova (NASDAQ:LIVN) Frequently Asked Questions
What is LivaNova's stock symbol?
LivaNova trades on the NASDAQ under the ticker symbol "LIVN."
How were LivaNova's earnings last quarter?
LivaNova PLC (NASDAQ:LIVN) posted its quarterly earnings results on Wednesday, May, 2nd. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.03. The business had revenue of $250.40 million for the quarter, compared to analysts' expectations of $245.18 million. LivaNova had a positive return on equity of 9.23% and a negative net margin of 1.99%. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.67 earnings per share. View LivaNova's Earnings History.
When is LivaNova's next earnings date?
What guidance has LivaNova issued on next quarter's earnings?
LivaNova issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.51.
What price target have analysts set for LIVN?
8 brokerages have issued 1-year price targets for LivaNova's stock. Their predictions range from $50.00 to $115.00. On average, they anticipate LivaNova's share price to reach $85.4286 in the next twelve months. View Analyst Ratings for LivaNova.
What are Wall Street analysts saying about LivaNova stock?
Here are some recent quotes from research analysts about LivaNova stock:
- 1. Needham & Company LLC analysts commented, "Wednesday (5/30/18) evening, the Services (CMS) announced that it opened a national coverage analysis (NCA) for vagal nerve stimulation (VNS) for treatment-resistant depression (TRD). LIVN offers the only implantable VNS devices in the US; while its VNS devices are FDA approved for both drug-resistant epilepsy and treatment-resistant depression, CMS currently only covers VNS for drug-resistant epilepsy. We think the most likely outcome of the NCA is the CMS provides coverage with evidence development which would make VNS available to patients enrolled in a registry. LIVN estimates the potential TRD market is ~10x that of drug-resistant epilepsy. We conservatively estimate this opportunity could be worth ~$9 per LIVN share and reiterate our Buy rating." (5/31/2018)
- 2. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (5/17/2018)
- 3. Canaccord Genuity analysts commented, "We remain HOLD-rated on shares of LIVN in the wake of their announcement that the company would purchase the remaining part of ImThera – an early-stage company focused on neuromodulation to treat obstructive sleep apnea – that it does not already own. While the technology fits synergistically within LIVN’s strong neuromodulation franchise to some degree, the call point will be different than its current offering (ENTs vs. neurosurgeons). The firm thinks it can leverage its growing OUS neuromodulation sales presence to drive some near-term ImThera revenue (expectations not disclosed) in Europe; however, we expect contributions will be minimal for the next few years at least, primarily on the basis of current reimbursement coverage, or lack thereof, and need for long-term data to catalyze ENT surgeons to adopt the therapy, according to our due diligence." (12/5/2017)
Who are some of LivaNova's key competitors?
Some companies that are related to LivaNova include SONOVA Hldg AG/ADR (SONVY), Varian Medical Systems (VAR), Masimo (MASI), GETINGE AB/ADR (GNGBY), CONMED (CNMD), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), BioLife Solutions (BLFS), Helius Medical Technologies (HSDT) and Fonar (FONR).
Who are LivaNova's key executives?
LivaNova's management team includes the folowing people:
- Mr. Damien McDonald, Chief Exec. Officer and Director (Age 53)
- Mr. David S. Wise, Chief Admin. Officer (Age 63)
- Thad Huston, Chief Financial Officer
- Mr. Douglas J. Manko, Chief Accounting Officer (Age 44)
- Ms. Karen King, VP of Investor Relations & Corp. Communications
Has LivaNova been receiving favorable news coverage?
News headlines about LIVN stock have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. LivaNova earned a daily sentiment score of 0.14 on Accern's scale. They also gave press coverage about the company an impact score of 47.02 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are LivaNova's major shareholders?
LivaNova's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.50%), Franklin Resources Inc. (6.63%), Dimensional Fund Advisors LP (3.00%), OppenheimerFunds Inc. (2.49%), Wells Fargo & Company MN (1.85%) and Millennium Management LLC (1.48%). Company insiders that own LivaNova stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Francesco Bianchi, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova.
Which major investors are selling LivaNova stock?
LIVN stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FIL Ltd, American Century Companies Inc., KBC Group NV, Redmile Group LLC, Dimensional Fund Advisors LP, Epoch Investment Partners Inc. and Bellevue Group AG. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Francesco Bianchi and Hugh M Morrison. View Insider Buying and Selling for LivaNova.
Which major investors are buying LivaNova stock?
LIVN stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Wells Fargo & Company MN, Point72 Asset Management L.P., Rothschild Asset Management Inc., BlackRock Inc., Neuberger Berman Group LLC, Millennium Management LLC and Allianz Asset Management GmbH. View Insider Buying and Selling for LivaNova.
How do I buy shares of LivaNova?
Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is LivaNova's stock price today?
One share of LIVN stock can currently be purchased for approximately $103.96.
How big of a company is LivaNova?
LivaNova has a market capitalization of $5.09 billion and generates $1.01 billion in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or $3.31 on an earnings per share basis. LivaNova employs 4,500 workers across the globe.
How can I contact LivaNova?
LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]
MarketBeat Community Rating for LivaNova (LIVN)
MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe LIVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
